Clinical interpretation and implications of whole-genome sequencing.
暂无分享,去创建一个
Euan A Ashley | Michael Snyder | Michelle Whirl-Carrillo | Russ B Altman | John P A Ioannidis | James M Ford | Atul J Butte | Themistocles L Assimes | Cuiping Pan | Teri E Klein | Rachel L. Goldfeder | Megan E. Grove | Frederick E Dewey | Benjamin A Goldstein | Thomas Quertermous | Sean P David | Colleen Caleshu | Matthew T Wheeler | T. Assimes | Michael P. Snyder | A. Butte | J. Ioannidis | R. Altman | E. Ashley | M. Whirl‐Carrillo | F. Dewey | K. Ormond | C. Caleshu | M. Wheeler | S. David | T. Klein | A. Yeung | H. Chaib | J. Merker | J. Ford | T. Quertermous | B. Goldstein | G. Enns | J. Bernstein | L. Boxer | M. Grove | Cuiping Pan | K. Kingham | Neda Pakdaman | K. Sakamoto | Jonathan A Bernstein | Hassan Chaib | Kelly E Ormond | Alan C Yeung | Megan E Grove | Rachel L Goldfeder | Gregory M Enns | Jason D Merker | Neda Pakdaman | Kerry Kingham | Kenneth Sakamoto | Linda Boxer | J. Ford | Michelle Whirl‐Carrillo
[1] David P Bick,et al. Making a definitive diagnosis: Successful clinical application of whole exome sequencing in a child with intractable inflammatory bowel disease , 2011, Genetics in Medicine.
[2] J. Fleiss. Measuring nominal scale agreement among many raters. , 1971 .
[3] Chong Shen,et al. Genome-wide association study in Han Chinese identifies four new susceptibility loci for coronary artery disease , 2012, Nature Genetics.
[4] Euan A Ashley,et al. A public resource facilitating clinical use of genomes , 2012, Proceedings of the National Academy of Sciences.
[5] T E Klein,et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype , 2012, Clinical pharmacology and therapeutics.
[6] Jonathan C. Cohen,et al. Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. , 2010, The New England journal of medicine.
[7] Patrizia Sola,et al. Exome Sequencing Reveals VCP Mutations as a Cause of Familial ALS , 2011, Neuron.
[8] R. Altman,et al. Pharmacogenomics Knowledge for Personalized Medicine , 2012, Clinical pharmacology and therapeutics.
[9] Nancy F. Hansen,et al. Accurate Whole Human Genome Sequencing using Reversible Terminator Chemistry , 2008, Nature.
[10] D. MacArthur,et al. Loss-of-function variants in the genomes of healthy humans. , 2010, Human molecular genetics.
[11] L. Esserman,et al. Genetic/familial high-risk assessment , 2010 .
[12] Larry N. Singh,et al. Secondary variants in individuals undergoing exome sequencing: screening of 572 individuals identifies high-penetrance mutations in cancer-susceptibility genes. , 2012, American journal of human genetics.
[13] Alexander A. Morgan,et al. Clinical assessment incorporating a personal genome , 2010, The Lancet.
[14] Patrick F. Chinnery,et al. Mitochondrial DNA polymerase-γ and human disease , 2006 .
[15] D. Absher,et al. Randomized Trial of Personal Genomics for Preventive Cardiology: Design and Challenges , 2012, Circulation. Cardiovascular genetics.
[16] C. Tyler-Smith,et al. Deleterious- and disease-allele prevalence in healthy individuals: insights from current predictions, mutation databases, and population-scale resequencing. , 2012, American journal of human genetics.
[17] Joseph K. Pickrell,et al. A Systematic Survey of Loss-of-Function Variants in Human Protein-Coding Genes , 2012, Science.
[18] L Gong,et al. The Clinical Pharmacogenomics Implementation Consortium: CPIC Guideline for SLCO1B1 and Simvastatin‐Induced Myopathy , 2012, Clinical pharmacology and therapeutics.
[19] Wei Lu,et al. Meta-analysis of genome-wide association studies identifies eight new loci for type 2 diabetes in east Asians , 2011, Nature Genetics.
[20] P. Radice,et al. Evidence of a founder mutation of BRCA1 in a highly homogeneous population from southern Italy with breast/ovarian cancer , 2001, Human mutation.
[21] Rena A. Godfrey,et al. The National Institutes of Health Undiagnosed Diseases Program: insights into rare diseases , 2011, Genetics in Medicine.
[22] angesichts der Corona-Pandemie,et al. UPDATE , 1973, The Lancet.
[23] J. Shendure,et al. Exome sequencing as a tool for Mendelian disease gene discovery , 2011, Nature Reviews Genetics.
[24] Tanya M. Teslovich,et al. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes , 2012, Nature Genetics.
[25] J. Dungan,et al. Carrier Testing for Severe Childhood Recessive Diseases by Next-Generation Sequencing , 2012 .
[26] R. Nussbaum,et al. Genetic/familial high-risk assessment: breast and ovarian. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.
[27] C. Croce,et al. BRCA1 5083del19 Mutant Allele Selectively Up-Regulates Periostin Expression In vitro and In vivo , 2008, Clinical Cancer Research.
[28] W. Grody,et al. ACMG recommendations for standards for interpretation and reporting of sequence variations: Revisions 2007 , 2008, Genetics in Medicine.
[29] Emily H Turner,et al. Actionable, pathogenic incidental findings in 1,000 participants' exomes. , 2013, American journal of human genetics.
[30] J. Mega,et al. Consortium ( CPIC ) guidelines for cytochrome P 450-2 C 19 ( CYP 2 C 19 ) genotype and clopidogrel therapy , 2011 .
[31] T E Klein,et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing: 2013 Update , 2013, Clinical pharmacology and therapeutics.
[32] J. Mega,et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update , 2013, Clinical pharmacology and therapeutics.
[33] J. Danesh,et al. Large-scale association analysis identifies new risk loci for coronary artery disease , 2013 .
[34] Euan A Ashley,et al. Performance comparison of whole-genome sequencing platforms , 2011, Nature Biotechnology.
[35] Marc S. Williams,et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing , 2013, Genetics in Medicine.
[36] P. Shannon,et al. Exome sequencing identifies the cause of a Mendelian disorder , 2009, Nature Genetics.
[37] Darlene Riethmaier,et al. Towards a Universal Clinical Genomics Database: The 2012 International Standards for Cytogenomic Arrays Consortium Meeting , 2013, Human mutation.
[38] Robert B. Hartlage,et al. This PDF file includes: Materials and Methods , 2009 .
[39] I. Tikhonova,et al. Genetic diagnosis by whole exome capture and massively parallel DNA sequencing , 2009, Proceedings of the National Academy of Sciences.
[40] S. Gross,et al. The kappa coefficient of agreement for multiple observers when the number of subjects is small. , 1986, Biometrics.
[41] F. Couch,et al. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. , 1997, The New England journal of medicine.
[42] M. Whirl‐Carrillo,et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing , 2011, Clinical pharmacology and therapeutics.
[43] P. Stenson,et al. The Human Gene Mutation Database: 2008 update , 2009, Genome Medicine.
[44] P. Chinnery,et al. Mitochondrial DNA polymerase-gamma and human disease. , 2006, Human molecular genetics.
[45] Omar E. Cornejo,et al. Phased Whole-Genome Genetic Risk in a Family Quartet Using a Major Allele Reference Sequence , 2011, PLoS genetics.
[46] P. Stankiewicz,et al. Whole-genome sequencing in a patient with Charcot-Marie-Tooth neuropathy. , 2010, The New England journal of medicine.
[47] Kenny Q. Ye,et al. An integrated map of genetic variation from 1,092 human genomes , 2012, Nature.
[48] James P Evans,et al. An informatics approach to analyzing the incidentalome , 2012, Genetics in Medicine.